Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Nekasa Nisida
Country: Botswana
Language: English (Spanish)
Genre: Technology
Published (Last): 27 December 2012
Pages: 483
PDF File Size: 14.22 Mb
ePub File Size: 11.65 Mb
ISBN: 332-9-62222-435-7
Downloads: 54957
Price: Free* [*Free Regsitration Required]
Uploader: Mikanos

Consequent to the fndings of the above exercise, the carrying amount of inventory has been written down by Rs. Quick Links for ranbaxylaboratories.

A, Italy Ranbaxy Malaysia Sdn. Dion Global Solutions Limited. Options are granted at the discretion of the committee to selected employees depending upon certain criterion.

Annual Reports

Rreport to the transaction, the Company has recorded a gain of Rs. Nifty bounces over ; Bharti languishes 17 Feb 10 Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance forward contractsoptions, currency swaps, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.

Daiichi Sankyo Propharma Co. Since the matter involves signifcant judgement and in view of the inherent uncertainty of the present situation, the actual amounts may differ eventually.

It also includes a demand of Rs.

Annual Reports & Presentations

Contingent liabilities and commitments to the extent not provided for As at As at 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on behalf of subsidiaries, to the extent of limits 6, ESOS provides that the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted.


Due to the nature of these disputes and also in view of signifcant uncertainty of outcome, the Annnual believes that the amount of exposure cannot be currently determinable. The Company has challenged the order before the Rfport Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable. The Company will issue shares to the Trust which will allocate the shares to the respective employees upon exercise of stock options from time to time under ESOP – The amount is excluding interest and penalty, if any.

The amount above represents the difference payable.

Annual Reports & Presentations | Sun Pharmaceutical Industries Ltd.

This scheme limits the maximum grant od options to an employee or a director at 30, in any given year. Your Account is not yet activated Click here to receive activation mail once again. The following are the outstanding derivative contracts entered into by the Company: The Company expects to resume API bulk shipments to EU countries from Toansa manufacturing facility upon receipt of clearances from relevant regulatory authorities.

RANBAXY Business Profile Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms for human tanbaxy careanimal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents. The Company is fully cooperating with this information request and is in dialogue with the US DOJ for submission of the requisite information.

The ineffectiveness arising from cash fow hedges which was recognised in Statement of Proft and Loss was not material. Related party disclosures A] Names of related parties Annuwl parties where control exists with whom no transactions have taken place during the current period or previous year: The same is expected to be resumed shortly.


Ranbaxy Laboratories Balance Sheet, Ranbaxy Laboratories Financial Statement & Accounts

The Company is in dialogue with these regulatory agencies and is addressing their concerns. Please do reach out to us at contactus reportjunction. It is the largest exporter of bulk drugs and pharmaceutical dosag.

Annal markets of US, Europe not so promising 27 Oct 09 Consequently, stock write off and other costs of Rs. Click here to change registered Email ID. Nifty pares losses; Ranbaxy,Cipla lead 25 Sep 09 As per the Scheme, the share exchange ratio has been proposed as 0.

Options lapse, if they are not exercised prior to the expiry date, which is three months from the date of the vesting. We are attempting to resolve this funny technical issue!

The Company expects to resume the operations shortly. Further, the Company has deposited Rs. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.

ESOS I and II provide that the grant price of options is to be determined at the average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant. As at 31 Marchthere are no such derivative contracts which are classifed as cash annusl hedges.